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Quality of lifeAbstract Malaysia is situated in Western Paciﬁc region which bears 36.17% of total diabetes
mellitus population. Pharmacist led diabetes interventions have been shown to improve the clinical
outcomes amongst diabetes patients in various parts of the world. Despite high prevalence of dis-
ease in this region there is a lack of reported intervention outcomes from this region. The aim of this
study was to evaluate the impact of a pharmacist led intervention on HbA1c, medication adherence,
quality of life and other secondary outcomes amongst type 2 diabetes patients.Method: Type 2 dia-
betes mellitus patients (n= 73) attending endocrine clinic at Universiti Kebangsaan Malaysia
Medical Centre (UKMMC) were randomised to either control (n= 36) or intervention group
(n= 37) after screening. Patients in the intervention group received an intervention from a pharma-
cist during the enrolment, after three and six months of the enrolment. Outcome measures such as
HbA1c, BMI, lipid proﬁle, Morisky scores and quality of life (QoL) scores were assessed at the
enrolment and after 6 months of the study in both groups. Patients in the control group did not
undergo intervention or educational module other than the standard care at UKMMC. Results:
HbA1c values reduced signiﬁcantly from 9.66% to 8.47% (P= 0.001) in the intervention group.
However, no signiﬁcant changes were noted in the control group (9.64–9.26%, P= 0.14). BMI
Impact of a pharmacist led diabetes mellitus intervention 41values showed signiﬁcant reduction in the intervention group (29.34–28.92 kg/m2; P= 0.03) and
lipid proﬁles were unchanged in both groups. Morisky adherence scores signiﬁcantly increased from
5.83 to 6.77 (P= 0.02) in the intervention group; however, no signiﬁcant change was observed in
the control group (5.95–5.98, P= 0.85). QoL proﬁles produced mixed results. Conclusion: This ran-
domised controlled study provides evidence about favourable impact of a pharmacist led diabetes
intervention programme on HbA1c, medication adherence and QoL scores amongst type 2 diabetes
patients at UKMMC, Malaysia.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf of King SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus is now considered a global health priority
due to increasing high prevalence, burden of co-morbidities
and premature mortalities (Roglic et al., 2005; Wild et al.,
2004). Malaysia is situated in the western paciﬁc (WP) region
which bears 138.2 million people (36.17%) with diabetes con-
tributing to the total of 382 million diabetes population world-
wide. The prevalence of diabetes amongst Malaysian adults
aged between 20 and 79 years was reported to be 10.1% in
2013 (Federation, 2013). Prevalence of diabetes in the Asian
population is predominant in the middle age group in contrast
to the western countries; amongst all the regions WP region
has the highest prevalence of diabetes in the age group of
40–59 year (Chan et al., 2009). The predominant prevalence
of diabetes in the younger age in Asian population compared
to their European counterparts is attributable to the changes
in the epidemiological, socioeconomic and genetic characteris-
tics of the Asian population over the past few decades (Ma and
Chan, 2013).
Diabetes is a life-long disease and constantly increasing inci-
dence of diabetes has drawn the attention of the healthcare
community to the need of effective management programmes.
In one such approach, the involvement of a pharmacist in dia-
betes management has been shown to improve patient out-
comes in various healthcare settings across the world (Collins
et al., 2011; Alhabib et al., 2014). Despite the high prevalence
of diabetes in Asia, majority of the existing studies regarding
the involvement of the pharmacists in diabetes originates from
the Western countries. There is scarcity of relevant studies such
as randomised controlled trials, from Malaysia. A prospective
study was conducted to evaluate the role of the pharmacists
in Diabetes Medication Therapy Adherence Clinic (DMTAC)
(Lim and Lim, 2010). Therefore, there is a need to demonstrate
the impact of a pharmacist intervention programme on dia-
betes care in Malaysia. Based on our knowledge, the present
study is the ﬁrst randomised control study in Malaysia measur-
ing the impact of the pharmacist educational programme.
The aim of this study was to evaluate the impact of a phar-
macist led diabetes management programme on type 2 diabetes
patients on HbA1c, medication adherence and quality of life.
2. Methods
2.1. Study design and setting
This randomised controlled study was conducted within
6 months in a secondary endocrine clinic at UniversitiKebangsaan Malaysia Medical Centre (UKMMC). The
recruitment and data collection were performed between
August 2013 and August 2014. Setting for pharmacist interven-
tion in this study consisted of a private counselling room at
UKMMC. The study was approved by Universiti
Kebangsaan Malaysia research ethics committee (Ref No.
UKM 1.5.3.5/244/NF-018-2012).
2.2. Patients and randomisation
Based on a previous study, the sample size required for
detecting the difference of 1% reduction with 1.2% standard
deviation in A1c (power of study = 80%, signiﬁcance = 5%)
was 30 patients for a two tailed study (Kelly and Rodgers,
2000). Considering a dropout rate of 20% in the comparable
intervention groups from the literature, 6 patients were added
to each group with 36 patients for each arm.
Patient registered for the day appointment and was diag-
nosed for poorly controlled diabetes mellitus type 2
(HbA1cP 8%) at UKMMC was recruited in this study.
Patients were included in the study only if the record of their
blood tests within the previous two months from the day of
enrolment was available in the clinic database and understand
either Malay or English language. Patients were excluded from
the study if they were diagnosed with any concurrent endocrine
disorder (such as thyroid disorders, obesity, and gestational
diabetes), cardiac heart failure, end stage renal disease, hepati-
tis or cancer. Patients were also excluded from the study if they
were enrolled in other concurrent educational programmes.
Simple random sampling was used in which a list of
random numbers was generated using the patients’ hospital
IDs and sample was collected from this list. After recruitment,
simple randomisation technique was followed for assigning the
subjects to either control or intervention group. Patients were
asked to handpick an envelope from the basket indicating
allocation to either control or intervention group.2.3. Standard care
The standard care of diabetes patients at UKMMC consisted
of a patient-physician meeting ranging from every four to nine
months. Patients with poor glycaemic control were referred to a
nurse diabetes educator for diabetes related education. In addi-
tion, patients received the standard pharmacy care upon their
visit for medication reﬁlls every 2–3 months. To measure the
effect of difference in the number of patient-physician meetings
on the outcomes, chi square test was used in the data analysis.
Patients in the control group received standard care only.
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Diabetes management programme in our study was called
Patient Education by Pharmacist Programme (PEPP). The
content of intervention was developed in accordance with
ADA guidelines (Association, 2013) and the Malaysian
Ministry of Health guidelines (Health, 2013) combined with
the results from the previous interventions. The summary of
the intervention content is attached as Appendix A. Patients
in intervention group received standard care and PEPP inter-
vention. The patients enrolled in the intervention group were
required to visit the hospital at the baseline, three months
and six months duration during the course of intervention.
At the enrolment, patients received counselling about diabetes,
its complications, diabetes medication, lifestyle modiﬁcations
and selfmonitoring of the disease. On the second visit, pharma-
cist reinforced the intervention about the lifestyle modi-
ﬁcations, medication adherence, and selfmonitoring. In
addition, pharmacist assessed the knowledge of the patients
about diabetes and complication components of education
and repeated the intervention if the pharmacist felt the need
for it after assessment. The pharmacist who performed the
intervention was registered with the Malaysian Board of
Pharmacy and did not take part in any speciﬁc training work-
shops before initiating the PEPP. Pharmacist delivered the
intervention face to face meetings however to curb the drop-
out rate, patients were contacted on the phone in case they
were unable to turn up for the scheduled meeting due to time
management. The data collection from the control group was
performed by an independent researcher and pharmacist had
no contact with the participants of control group.2.5. Outcome Measures
Table 1 shows the summary of outcome assessments and inter-
vention performed at each visit. Medication adherence and
QoL questionnaires were completed by the patients in majority
of cases. MMMAS is a self-administered instrument but
sometimes pharmacist or researcher assisted the patients to
overcome the non-responsiveness by some participants. This
practice has been reported to be acceptable in the literature
(Al-Qazaz et al., 2010). Additional information about inter-
pretation of the questionnaires has been elaborated in




Lipid proﬁle (LDL, HDL, total cholesterol, triglycerides)
Body mass index
Medication adherence (modiﬁed Morisky medication adherence scale)
Quality of life (EQ5D-3L)
Review of patients’ knowledge about diabetes management
Standard care
PEPP intervention2.6. Statistical analyses
The Statistical Package for the Social Sciences (SPSS, Version
22 Inc., Chicago, IL, USA) for Windows was used in the data
analysis for this study. Baseline characteristics of both groups
were compared by using chi-square test for nominal/ordinal
variables and suitable t-test for continuous variables. The
assumptions for statistical tests such as normality and sample
size were complied before applying the tests. The results were
set to be signiﬁcant at p< 0.05.
3. Results
Of the 73 eligible patients, 37 patients were randomised to the
intervention group and 36 patients were randomised to the
control group. A total of 66 patients completed the study.
Fig. 1 shows the trial ﬂow diagram prepared in accordance
with the CONSORT guidelines. The baseline characteristics
of both groups are presented in Table 2. There was no
signiﬁcant difference in the baseline demographic and clinical
characteristics of the participants. The ﬁrst session of the inter-
vention took approximately 35–45 min and second session was
completed in approximately 20–30 min.
3.1. Clinical outcomes
The changes in the primary and secondary clinical outcomes of
the study are presented in Table 3. Measurement of HbA1c
was the primary outcome in our study; mean HbA1c values
showed signiﬁcant decline in the intervention group compared
to the control group (p= 0.04). BMI decreased signiﬁcantly in
the intervention group participants but the change was non-
signiﬁcant compared to the change in the control group
(p> 0.05). Lipid proﬁles of the patients showed no signiﬁcant
changes in both groups over the study period. Table 4 shows
the percentage of patients who met ADA target of 7%
HbA1c for glycaemic control and Fig. 2 is the graphical repre-
sentation of the changes in glycaemic control before and after
intervention in the control and the intervention groups.
3.2. Medication adherence (MMMAS)
Medication adherence was signiﬁcantly improved in the
intervention group (p= 0.03) unlike the correspondingn during study duration.
Control group Intervention group
0 Month 3 Months 6 Months 0 Month 3 Months 6 Months
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Figure 1 Trial ﬂow diagram in accordance with CONSORT guidelines (CONSORT, Consolidated Standards of Reporting Trials).
Table 2 Baseline demographic and clinical characteristics of participants (n= 66).
Control (n= 33) Intervention (n= 33) Total p-value
Age mean ± SD 57.12 ± 10.78 57.42 ± 7.17 0.89
Marital status
Married (%) 93.9 90.9 0.64a
Gender
Male 14 (42.4%) 13 (39.4%) 27 (40.9%)
Female 19 (57.6%) 20 (60.6%) 39 (59.1%) 0.80a
Race
Malay 20 (60.6%) 18 (54.5%) 38 (57.6%)
Chinese 8 (24.2%) 7 (21.2%) 15 (22.7%)
Indian 5 (15.2%) 8 (24.2%) 13 (19.7%) 0.65a
Duration of diabetes (years)
1–5 7 (24.1%) 7 (23.3%) 14 (23.7%) 0.90a
5–10 10 (34.5%) 12 (40%) 22 (37.3%)
>10 12 (41.4%) 11 (36.7%) 23 (39.0%)
A1c (%) Mean ± SD 9.64 ± 1.41 9.66 ± 1.57 0.94
Medication
Oral 17 (53.1%) 12 (37.5%) 29 (45.3%) 0.34b
Insulin only 1 (3.1%) 3 (9.4%) 4 (6.3%)
Oral + insulin 14 (43.2%) 17 (53.1%) 31 (48.4%)
Adherence level
Poor 16 (48.5%) 19 (57.6%) 35 (53%) 0.45a
Medium/high 17 (51.5%) 14 (42.6%) 31 (47%)
a Chi-square test.
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The percentage of patients with poor adherence signiﬁcantly
decreased from the baseline to the end of the study in the
intervention group (p= 0.02); however this change was non-
signiﬁcant between the control and the intervention groups
(p= 0.08).3.3. Quality of life (EQ-5D-3L)
There was no baseline difference in the QoL proﬁles in both
groups. Amongst the total ﬁve dimensions, mobility
(p= 0.03) and anxiety (p< 0.0001) proﬁles showed signiﬁcant
changes within the intervention group. However no signiﬁcant
Table 3 Changes in outcome parameters at the start and end of the study in control and intervention groups.
Outcome Control group (n= 33) Intervention group (n= 33) p-value
(control vs. intervention)
Baseline Final p-value Baseline Final p-value
HbA1c (%) 9.64 ± 1.45 9.26 ± 1.61 0.14 9.66 ± 1.57 8.47 ± 1.61 0.001a 0.04a
FBS (mmol/l) 9.63 ± 3.17 9.71 ± 4.24 0.94 10.58 ± 3.21 9.5 ± 3.50 0.15 0.86
BMI (kg/m2) 28.17 ± 4.57 27.97 ± 4.44 0.07 29.34 ± 5.22 28.92 ± 5.16 0.03a 0.44
TC (mmol/l)b 4.95 ± 1.26 4.99 ± 1.41 0.81 5.44 ± 1.69 5.66 ± 1.59 0.46 0.10
HDL-C (mmol/l)b 1.28 ± .32 1.34 ± 0.35 0.10 1.39 ± 0.47 1.44 ± 0.48 0.40 0.36
LDL-C (mmol/l)b 2.77 ± 1.01 2.86 ± 1.10 0.52 3.24 ± 1.63 3.27 ± 1.38 0.88 0.35
Triglycerides (mmol/l)b 1.53 ± 0.55 1.51 ± 0.86 0.90 1.66 ± 0.78 1.88 ± 1.09 0.28 0.13
Poor adherence (%) 16 (48.5%) 17 (51.5%) 0.8 19 (57.6%) 10 (30.3%) 0.02a 0.08
MMMAS scores 5.95 ± 1.51 5.98 ± 1.50 0.85 5.83 ± 1.84 6.77 ± 1.76 0.02a 0.03a
All values are presented in Mean ± SD except poor adherence which is shown in percentage; FBS, fasting blood sugar; TC, total cholesterol;
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; MMMAS, modiﬁed Morisky medication adherence
scale.
a Shows statistical signiﬁcance.
b Some data missing.
Table 4 Number of participants who achieved ADA target of
glycaemic control.
Outcome Control PEPP X2 (p-value)
No. of patients
<7% HbA1c 4 (12.1%) 6 (18.2%) 0.47 (0.49)
<8% HbA1c 7 (21.2%) 15 (45.2%) 4.36 (0.037a)
a Signiﬁcant at p< 0.05.
Figure 2 (a) Mean baseline and ﬁnal HbA1c values in control
and intervention groups and (b) mean change in HbA1c values
during study duration.
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Analysis of EQ-5D-3L VAS scores showed no signiﬁcant
changes between two groups despite the signiﬁcant improve-
ment in the VAS scores of the intervention group (p= 0.03)
at the end of study (Table 5).
3.4. Other outcomes
Chi-square analysis showed there was no meaningful
difference in the standard care between the control and the
intervention groups at the end of the study (p> 0.05).
3.5. Sustainability of outcomes
The comparison of mean HbA1c values after 6 months of
second intervention demonstrated that there was no signiﬁcant
difference between participants who were enrolled in either
intervention or control group (intervention group mean
HbA1c = 8.79 ± 1.45, control group mean HbA1c =
8.72 ± 1.46; p= 0.88). However the dropout rate of partici-
pant was increased at this follow up and data of 25 participants
in the intervention group and 22 participants in the control
group were available.
4. Discussion
Our study was designed to measure the impact of pharmacist
intervention on HbA1c levels in type 2 diabetes patients.
Outcomes of the study showed reduction in HbA1c levels in
the intervention group were signiﬁcantly better than the reduc-
tion in the control group. The HbA1c reduction of 1.19%
(SD= 1.36) in our study is clinically relevant as well as sta-
tistically signiﬁcant. Our results were comparable to the ﬁndings
of a meta-analysis by Collins et al. (2011). It was reported that
randomised controlled trials within 6 month duration of phar-
macist intervention produced a mean change of 0.95% in
HbA1c levels with conﬁdence interval of 95% (Collins et al.,
2011).Another ﬁnding of themeta-analysis showed aqualitative
trend towards higher mean of HbA1c reductions in studies with
pharmacist intervention longer than 6 months. Our study was
restricted to 6 months of duration therefore we compared the
results of our study primarily with RCTs spanning six months.
Table 5 Summary of EQ-5D-3L data for quality of life domains.
Outcome Patients reporting problems in control group Patients reporting problems in intervention group X2 (p-value)
(control vs.
intervention)
Baseline Final X2 (p-value) Baseline Final X2 (p-value)
Mobility 8 (24.2%) 5 (15.2%) 0.86 (0.35) 14 (42.4%) 6 (18.2%) 4.52 (0.03*) 1.16 (0.28)
Selfcare 2 (6.1%) 0 2.06 (0.15) 2 (6.1%) 0 2.06 (0.15) 1.01 (0.31)
Usual activities 4 (12.1%) 4 (12.1%) 0.00 (1.00) 3 (9.1%) 1 (3%) 1.06 (0.30) 3.14 (0.07)
Pain/discomfort 14 (42.4%) 8 (24.2%) 2.45 (0.11) 14 (42.4%) 9 (27.3%) 1.66 (0.19) 0.77 (0.37)
Anxiety/depression 13 (39.4%) 9 (27.3%) 1.20 (0.30) 12 (36.4%) 0 14.66 (0.0001*) 3.26 (0.07)
EQ-5D VAS
Mean score ± SD 70.60 ± 18.31 77.12 ± 11.52 0.04* 75.06 ± 16.62 82.45 ± 10.26 0.007* 0.05*,a
a Analysis using t-test.
* Shows statistical signiﬁcance.
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to other ﬁndings. A randomised controlled trial reported sig-
niﬁcant reduction of 0.6% in the intervention group after six
months of pharmacist intervention (Mehuys et al., 2011).
Smaller baseline HbA1c values in this study explained the
small ﬁnal changes in the HbA1c compared to our study;
patients with higher HbA1c values showed greater improve-
ment in the ﬁnal values (Choe et al., 2005; Ragucci et al.,
2005). In a second six month randomised control trial, the
HbA1c values in the intervention group decreased signiﬁcantly
by 0.8% in contrast to increase in the control group (Jarab
et al., 2012). Another study with 6 month pharmacist interven-
tion reported 0.8% reduction of HbA1c values in the interven-
tion group. This reduction was clinically signiﬁcant but was
reported to be statistically non-signiﬁcant against control
group. The non-signiﬁcant changes were explained by the
structure of the intervention leading to the contamination of
both groups in addition to the relatively smaller baseline
HbA1 values (Phumipamorn et al., 2008). Apart from RCTs,
studies with other experimental designs also produced similar
results after six months of pharmacist intervention. A prospec-
tive 6 month study produced 1.9% decrease in HbA1c levels
from the baseline to the end of the study period.
Intervention was intensive with a high baseline HbA1c value
of 10.8% (Rothman et al., 2003). In a 6 month retrospective
chart review, patients were reported to have 1.4% reduction
at the end of the study after frequent and indeﬁnite meetings
between patients and pharmacist (McCord, 2006). Results of
our study showed signiﬁcant beneﬁts of pharmacist interven-
tion in Malaysian type 2 diabetes patients and further support
the ﬁndings of the previous studies from the other parts of the
world.
Currently, the target HbA1c value for diabetes is set at
below 7% by ADA and below 6.5% by the Malaysian
Ministry of Health. In our study, 18.2% participants in the
intervention group achieved this target. The percentage of
patients who achieved ADA target in our study is lesser than
other RCTs; 28% (Phumipamorn et al., 2008), 23.4% (Jarab
et al., 2012), 38.4% (McWhorter and GM, 2005) patients
achieved the ADA target in other studies. This can be explained
by the higher baseline HbA1c values in our study. To meet the
ADA target, our study participants were required to produce a
greater change in the HbA1c. Fasting blood sugar measure-
ments were excluded from the ﬁnal analysis due to the noncom-
pliance amongst patients with fasting before the test. Thus the
results were considered inappropriate for the analysis.This study provides the evidence of beneﬁts of pharmacist
intervention in Malaysian population. Previous studies have
shown that care of quality and access for diabetes varies across
socioeconomic conditions and there are differences in diabetes
complications, end points and quality of care amongst differ-
ent ethnicities (Lanting et al., 2005; Oyetayo et al., 2011).
Therefore, results obtained from the other parts of the world
with different ethnic and socioeconomic compositions are
not generalisable for the local population. Our results demon-
strate the positive impact on the quality of the pharmacist care
in diabetes in Malaysia. Malaysian population is multi-ethnic;
however our study did not evaluate the characteristics of
individual ethnicities. Future studies that evaluate the impact
of ethnic difference in Malaysian population on glycaemic out-
comes can be conducted. Currently there is an ongoing phar-
macist managed Medication Therapy Adherence Clinic
(MTAC) for diabetes in Malaysia. Patients are required to
meet the pharmacist after every one or two months once they
are enrolled in the programme. Findings of this study showed
signiﬁcant changes in HbA1c with patient pharmacist meetings
being held after three months of enrolment. Therefore it may
be suggested to eliminate the frequent meetings between
patient and pharmacist in MTAC. Eliminating the excess
meetings will facilitate the more time efﬁcient use of pharma-
cist manpower in MTAC. However future studies that investi-
gate and compare the impact of meeting schedule on glycaemic
control for longer period are needed before drawing a deﬁnite
conclusion.
In our study at 3 months of follow up there was signiﬁcant
difference between both groups however the difference waned
off at 6 months. This result appears to be in agreement with
the trend noticed in the literature (Sarkadi and Rosenqvist,
2004; Mehuys et al., 2011). It proposes that pharmacist inter-
vention may need to be reinforced after a gap longer than
3 months for sustainability of beneﬁcial effect.
In our study there were no signiﬁcant changes in the lipid
proﬁle before and after the intervention. Likewise, one study
on pharmacist managed diabetes service found that the lipid
proﬁles showed no signiﬁcant changes from the baseline to
the ﬁnal examination (Kelly andRodgers, 2000). However there
is ample evidence of signiﬁcant improvement in lipid proﬁles
along with the glycaemic control after pharmacist intervention
(Phumipamorn et al., 2008; Al Mazroui et al., 2009; Oyetayo
et al., 2011). Although there was signiﬁcant improvement in
the lipid proﬁles of these studies, the ﬁnal values did not meet
the target ADA values. The lack of improvement in lipid
46 M. Butt et al.proﬁles despite improved glycaemic control in our study may be
attributable to the ADA ﬁndings about dyslipidaemia. It was
reported that glycaemic control alone will not result in the com-
plete recovery of diabetes related dyslipidaemia and initiation of
lipid lowering agents becomes necessary (Association, 2002;
2004). Our study lacks the data on lipid lowering therapy of
the participants and therefore a deﬁnite conclusion cannot be
drawn. The baseline glycaemic values showed a signiﬁcant sta-
tistical correlation with the ﬁnal changes in the HbA1c values
(p= 0.01). This observation is consistent with the previous evi-
dence (Choe et al., 2005; Ragucci et al., 2005; Oyetayo et al.,
2011).
Despite the signiﬁcant changes in adherence scores reported
in the intervention group, the status of average mean adher-
ence (poor, moderate or high) remained unchanged before
and after the intervention. The participants were moderately
adherent to their medication before and after the intervention
(5.83 vs 6.77; p= 0.03). Comparing the results to the previous
studies, most studies showed the positive impact of pharmacist
intervention amongst diabetes patients (Al Mazroui et al.,
2009; Borges et al., 2010; Mitchell et al., 2011; Jarab et al.,
2012) however, an absence of any improvement in adherence
after pharmacist intervention was also reported (Odegard
et al., 2005). A lack of gold standard to measure medication
adherence hinders the quantiﬁcation of adherence scores. It
is not possible to compare the degree of improvement in med-
ication adherence across various studies.
The improvement in QoL anxiety proﬁle of our study is
consistent with some previously published studies. Scott and
colleagues demonstrated there was an improvement in QoL
anxiety measure amongst pharmacist managed diabetes
patients (Scott et al., 2006). In another 12 month study, mental
component summary (MCS) of QoL questionnaire showed
improvement after pharmacist intervention but physical com-
ponent was not signiﬁcantly affected (Johnson et al., 2008).
An interesting ﬁnding showed a high signiﬁcant (p= 0.007)
improvement in EQ-5D of VAS scores in the intervention
group over 6 months. This may have been facilitated by aTable A1 Constituents of intervention programme (PEPP) used in
Unit Descriptio
Diabetes mellitus and complications of diabetes  Pictoria
 Concise
 Manage
Hypoglycaemia and hyperglycaemia  Pictoria
 Manage
 Target
Diabetes medication  Pictoria
 Emphas
 Pharma






Selfmonitoring and follow up  Importa
 How to
 When tsigniﬁcant improvement in the anxiety proﬁle of participants
as a result of intervention. VAS scores represent selfrated
health state of patients and patients will likely rate their health
state better when depression is removed or alleviated from
their lives. A high percentage of patients in the intervention
group presented with problems in mobility at the baseline,
therefore probability of improvement during the study period
was high with signiﬁcant improvement was reported.
Majority (>87.9%) of the patients in both groups pre-
sented with no problems in the self-care and usual activity
dimension at the baseline; therefore chances of meaningful
improvement were either very slim or null. In case of pain/dis-
comfort there was substantial improvement amongst patients
at the end of the study however this did not reach the statistical
signiﬁcance.5. Limitations
Findings of our study have highlighted the favourable impact of
the pharmacist intervention on diabetes management.
Nevertheless, these ﬁndings should be interpreted with caution
due to several limitations. An important limitation was that
our study might not have been fully representative of general
diabetes population since the participation in the study was
voluntary. There was incomplete record about the total number
of patients who were approached to participate in the study and
reason they were excluded from the study. The short duration of
the study was a limitation to measure the sustainability of the
favourable outcomes. There was lack of a strict protocol for
the baseline clinical values; we used the values in range extending
frompast week to past twomonths. The valuesmeasured during
that interval may have been changed at the baseline visit.
Further studies which measure outcomes at the lesser ﬂexibility
will increase reliability of the results. Another limitation is the
exclusion of those patients who could not understand either
Malay orEnglish language. Excluded patientsmay have had dif-
ferent clinical characteristics and presentation. Future studiesthe study.
n
l illustration of diabetes signs and symptoms
pictorial illustration of diabetes complications
ment of diabetes complications
l illustration of signs and symptoms
ment of hypoglycaemia and hyperglycaemia
levels
l illustration of correct insulin administration sites and technique
is on medication adherence
cist was not authorised for pharmacotherapy modiﬁcations
l illustration of suitable exercises for diabetes patients
tion before physical activity and warning signs in case of emergency
l illustration of plate method by ADA
ive session about food groups
nce of selfmonitoring
keep the record of blood glucose in the diaries
o contact the pharmacist for next appointment
Impact of a pharmacist led diabetes mellitus intervention 47with similar design at multiple centres can be conducted to pro-
duce more reliable and generalisable results.
6. Conclusion
A pharmacist led diabetes mellitus management programme
facilitated the improvement in glycaemic control, medication
adherence and quality of life amongst type 2 diabetes mellitus
patients. The results of the present study support the evidence
on the beneﬁts of pharmacy related management programmes
for diabetes from the other parts of the world.
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Appendix A
PEPP consisted of a ﬂip chart with multiple units. The high-
lights of each unit are listed below.
See Table A1.
Appendix B
B.1. Interpretation of questionnaires
B.1.1. Modiﬁed Morisky medication adherence scale
Scoring of Morisky scale was performed according to the vali-
dated Malay version of the questionnaire. Interpretation of
scores is given below:
Low adherence (<6).
Medium adherence (6 to <8).
High adherence (=8).
B.1.2. Quality of life (EQ-5D-3L)
Each dimension on the questionnaire has 3 levels: no prob-
lems, some problems, extreme problems coded as 1, 2, and 3
respectively. For interpretation, Level 2 and 3 were combined
into one value and labelled ‘problems’. The EQ VAS records
the respondent’s self-rated health on a vertical, visual analogue
scale where the endpoints are labelled as ‘best imaginable
health state’ and ‘worst imaginable health state’.
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